PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo offers hope for myelofibrosis patients who failed standard therapy
Disease control CompletedThis study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease no longer responded well to standard JAK-inhibitor treatment. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo aims to tame deadly transplant complication
Disease control CompletedThis phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a Pre-Transplant drug boost survival in myelofibrosis?
Disease control CompletedThis phase 2 trial looked at whether giving a JAK inhibitor (ruxolitinib) before a donor stem cell transplant helps people with myelofibrosis. The study enrolled 61 patients with primary or secondary myelofibrosis. The goal was to see if this approach improves survival and reduce…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Drug cocktail shows promise against rare bone marrow cancers
Disease control CompletedThis study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. While the treatment aims to control the disease, it is not a cure, a…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Bomedemstat extension trial tests Long-Term safety for blood cancer patients
Disease control CompletedThis study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, sp…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Scientists probe the root cause of a rare bone marrow disease
Knowledge-focused CompletedThis completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understan…
Matched conditions: PRIMARY MYELOFIBROSIS
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC